Literature DB >> 17885489

Prognostic value of measurements of angiogenesis in serous carcinoma of the ovary.

Julia E Palmer1, Louis J Sant Cassia, Clive J Irwin, Alan G Morris, Terence P Rollason.   

Abstract

The study objective was to determine whether tumor vascularity correlates with patient survival, to compare newer semiautomated methods of angiogenesis assessment to older methods, and to determine if advanced image analysis methods can offer useful patient outcome data in serous ovarian cancer. Using the specific endothelial marker CD34, microvessel determinations were quantified in 132 serous ovarian tumors by manual counting at final magnifications of x 200 and x 400 in the most highly vascular areas. Computer-assisted image analysis microvessel counts, endothelial area estimates, and minimum spanning tree (MST) analysis of capillary architecture, which involves assessment of intercapillary distances, were correlated with traditional manual techniques.Manual, semiautomated, and advanced image analysis methods were found to be highly reproducible and express strong correlation with one another. Univariate cyclooxygenase analysis revealed angiogenesis parameters to be highly significant predictors for overall survival (OS) and disease-free survival. Multivariate cyclooxygenase analysis revealed maximum MST (P = 0.009), length MST (P = 0.005), 1 nearest neighbor (P <or= 0.01) and mean microvessel density (x 400) (P = 0.0001) to be significant predictors for OS, and mean endothelial area (P <or= 0.01) and stage (P = 0.001) significant predictors for disease-free survival. Despite showing prognostic significance on univariate analysis, most clinicopathologic parameters did not retain independent significance on multivariate analysis. Microvessel determination is an independent prognostic indicator for survival in patients with serous ovarian carcinoma. Computer-assisted image analysis is a highly reproducible method of assessment capable of accurately evaluating tumor vascularity. Minimum spanning tree analysis of capillary architecture was found to be the strongest prognosticator for OS, suggesting this to be a promising marker.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17885489     DOI: 10.1097/pgp.0b013e318063bed7

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  7 in total

1.  Characterization of Adnexal Masses Using Contrast-Enhanced Subharmonic Imaging: A Pilot Study.

Authors:  Lauren J Delaney; Priscilla Machado; Mehnoosh Torkzaban; Andrej Lyshchik; Corinne E Wessner; Christine Kim; Norman Rosenblum; Scott Richard; Kirk Wallace; Flemming Forsberg
Journal:  J Ultrasound Med       Date:  2019-11-26       Impact factor: 2.153

2.  Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.

Authors:  Rebecca L Stone; Keith A Baggerly; Guillermo N Armaiz-Pena; Yu Kang; Angela M Sanguino; Duangmani Thanapprapasr; Heather J Dalton; Justin Bottsford-Miller; Behrouz Zand; Rehan Akbani; Lixia Diao; Alpa M Nick; Koen DeGeest; Gabriel Lopez-Berestein; Robert L Coleman; Susan Lutgendorf; Anil K Sood
Journal:  Cancer Biol Ther       Date:  2014-04-23       Impact factor: 4.742

3.  Lack of correlation between microvascular density and pathological features and outcomes in sinonasal and oral mucosal melanomas.

Authors:  Elizabeth H Kerr; Dezhi Wang; James S Lewis; Nasser Said-Al-Naief; Omar Hameed
Journal:  Head Neck Pathol       Date:  2011-03-19

4.  Study on the characteristics of contrast-enhanced ultrasound and its utility in assessing the microvessel density in ovarian tumors or tumor-like lesions.

Authors:  Junyan Wang; Faqin Lv; Xiang Fei; Qiuli Cui; Longxia Wang; Xuewen Gao; Zhixian Yuan; Qian Lin; Yali Lv; Aijun Liu
Journal:  Int J Biol Sci       Date:  2011-05-13       Impact factor: 6.580

5.  Current status of bevacizumab in advanced ovarian cancer.

Authors:  Federica Tomao; Anselmo Papa; Luigi Rossi; Davide Caruso; Pierluigi Benedetti Panici; Martina Venezia; Silverio Tomao
Journal:  Onco Targets Ther       Date:  2013-07-22       Impact factor: 4.147

6.  Antivascular therapy for epithelial ovarian cancer.

Authors:  Francois P Duhoux; Jean-Pascal Machiels
Journal:  J Oncol       Date:  2009-12-23       Impact factor: 4.375

7.  Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.

Authors:  Cécile Le Page; David G Huntsman; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  Cancers (Basel)       Date:  2010-05-26       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.